Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion.
about
Assessment of BED HIV-1 incidence assay in seroconverter cohorts: effect of individuals with long-term infection and importance of stable incidenceInter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infectionHIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, BrazilChanges in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohortsMolecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western KenyaDetection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studiesUse of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infectionHIV testing in 2006: issues and methods.Viral and Host Characteristics of Recent and Established HIV-1 Infections in Kisumu based on a Multiassay Approach.A comparison of biomarker based incidence estimatorsEstimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking routePrevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil.Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay.Screening for acute HIV infections and estimating HIV incidence among female sex workers from low-grade venues in Guangxi, China.A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assayTrends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia, 1999-2002.Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria.The potential role of biomarkers in HIV preventive vaccine trialsThe effect of sample handling on cross sectional HIV incidence testing results.Timing and order of transmission events is not directly reflected in a pathogen phylogeny.Recent HIV-1 infection: identification of individuals with high viral load setpoint in a voluntary counselling and testing centre in rural Mozambique.HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy.Analysis of HIV using a high resolution melting (HRM) diversity assay: automation of HRM data analysis enhances the utility of the assay for analysis of HIV incidence.Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India.Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.Antibody maturation and viral diversification in HIV-infected women.Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests.Evaluation of a multiplex assay for estimation of HIV-1 incidence.Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043).Estimated incidence and genotypes of HIV-1 among pregnant women in central Brazil.Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trialAssociation of pol diversity with antiretroviral treatment outcomes among HIV-infected African children.Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assayAssociation of recent HIV infection and in-utero HIV-1 transmission.Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes.Trends of HIV-1 incidence with credible intervals in Sweden 2002-09 reconstructed using a dynamic model of within-patient IgG growthAntibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B.
P2860
Q28477339-B0B3AE56-BC82-4328-B794-6FDA6A3970BAQ28534491-D52BD166-72D8-4BA1-A677-AC94DF793745Q28539348-E0532661-EE6A-4160-B4CD-B14811015AA0Q28542085-5F8C0170-AC47-4813-9999-BF4BF0CEB307Q28550140-F23D99E4-AABD-437C-B7E4-166D941A8FD5Q28730904-34CE95AD-2BFC-41DE-96C4-614B7CADC5DEQ28743210-A3086B7E-8F11-4DE4-B396-B626C5B3F1EAQ30357130-C96D6123-8F90-4C30-A41C-C1CB7830EABEQ30830042-37EE6C56-8473-4AB3-95DB-A2385D849C7DQ33509017-BFF9A9E9-1EDF-4767-983B-66D78E72E2ABQ33550575-6DDC40B6-73EE-4353-8C1B-5BA4CEA91886Q33643767-F40DD170-64CF-4215-8993-D97956A86E87Q33719217-6F817309-1981-4355-AA7B-39D0F9B2CCEBQ33740610-90017CC6-D8EC-4E1D-953A-91B2E905A0C2Q33812743-AFBF49CD-8688-4EA1-9600-0036F7B99E00Q33916829-F6A8176F-BEF6-4FFA-BC9A-42B8B62C3FD9Q33991968-72E590D9-3942-41E3-8C35-920004948FCEQ34019213-C79F4F24-870E-4C1F-8E59-3C4D66D4BCC8Q34059957-AF1B9F51-B46A-4387-8733-110675077DE1Q34064330-98EF8E17-3C17-4751-9CE3-B08060192B27Q34064859-4E8FE537-CE2F-4C6C-9B07-D4A2D919F192Q34171462-AC8563C8-7657-4888-880C-BEB4A8D85546Q34203609-F1C5938B-426B-461B-A15B-732295043243Q34512320-200CE20F-64FF-4F30-B5C2-C8D02C1277FBQ34514182-6C8B41E8-EFAF-4BE3-A5E7-04BAC42DE8BBQ34598155-B258ECAA-392B-402B-B88D-539DC8B47C93Q34608508-716703C5-A877-4841-A82D-260BADBF4A25Q34683831-303E7E19-71F5-45D8-8EF5-AB0AFD07B03CQ34745421-C77BB739-214C-4BF1-A087-D77E4DBCFEDFQ34848161-07D13267-7AE2-4ED0-8395-BEE96419F6A7Q35041199-3069CD47-968A-4778-B618-437E38E3FF79Q35043592-E7E8F6CD-44F0-4FA5-AD8A-B837990C09C9Q35060472-B92F0CCE-C75C-4410-B2D5-17C086C47980Q35080053-439306F5-366D-44BF-A142-25B62F95E62CQ35273371-AF04E30A-D580-4270-896B-E1D6AF7F5A9DQ35688075-3514D835-C4C3-48C2-8C20-050448DB8031Q35690562-482AE281-400A-4E63-B492-ADA4D92D8FFDQ35905630-CEF1E6D2-EDAD-4767-9F36-11BB90C5D094Q35965218-6B570B15-9A46-46E7-8D0B-EFB76709C2A8Q35985816-F8FFF12F-5236-40F0-847D-5F04FD46BFAA
P2860
Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Performance characteristics of ...... y virus type 1 seroconversion.
@ast
Performance characteristics of ...... y virus type 1 seroconversion.
@en
Performance characteristics of ...... y virus type 1 seroconversion.
@nl
type
label
Performance characteristics of ...... y virus type 1 seroconversion.
@ast
Performance characteristics of ...... y virus type 1 seroconversion.
@en
Performance characteristics of ...... y virus type 1 seroconversion.
@nl
prefLabel
Performance characteristics of ...... y virus type 1 seroconversion.
@ast
Performance characteristics of ...... y virus type 1 seroconversion.
@en
Performance characteristics of ...... y virus type 1 seroconversion.
@nl
P2093
P2860
P1476
Performance characteristics of ...... y virus type 1 seroconversion.
@en
P2093
Bharat S Parekh
Chou-Pong Pau
J Steven McDougal
Susan Kennedy
Trudy Dobbs
P2860
P304
P356
10.1128/JCM.42.6.2623-2628.2004
P407
P577
2004-06-01T00:00:00Z